AACP
PBYI icon

Advantage Alpha Capital Partners’s Puma Biotechnology PBYI Stock Holding History

Advantage Alpha Capital Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,796
Closed -$20.7K – 160
2024
Q4 		$20.7K Sell
6,796
-101,333
-94% -$295K ﹤0.01% 149
2024
Q3 		$276K Buy
+108,129
New +$327K 0.06% 160

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Advantage Alpha Capital Partners's PBYI Position: Q1 2025 in Review

Advantage Alpha Capital Partners sold out of Puma Biotechnology (PBYI) in Q1 2025, closing a stake of 6,796 shares — an estimated $20.7K sold.

Advantage Alpha Capital Partners first reported a position in PBYI in Q3 2024 and held it in 2 quarters. The position peaked at $276K in Q3 2024. 116 funds tracked by Wall St. Rank hold PBYI as of Q1 2025.

  • Advantage Alpha Capital Partners reported no remaining Puma Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 6,796 Puma Biotechnology shares in Q1 2025, an estimated $20.7K.
  • Advantage Alpha Capital Partners first reported a position in Puma Biotechnology in Q3 2024 and held it in 2 quarters.
  • Advantage Alpha Capital Partners's Puma Biotechnology position peaked at $276K in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q1 2025, filed 14 May 2025.